JP5658568B2 - 高密度リポタンパク質様ペプチド−リン脂質足場（「ｈｐｐｓ」）ナノ粒子 - Google Patents

高密度リポタンパク質様ペプチド−リン脂質足場（「ｈｐｐｓ」）ナノ粒子 Download PDF

Info

Publication number
JP5658568B2
JP5658568B2 JP2010537225A JP2010537225A JP5658568B2 JP 5658568 B2 JP5658568 B2 JP 5658568B2 JP 2010537225 A JP2010537225 A JP 2010537225A JP 2010537225 A JP2010537225 A JP 2010537225A JP 5658568 B2 JP5658568 B2 JP 5658568B2
Authority
JP
Japan
Prior art keywords
peptide
hpps
lipid
nanoscaffold
dir
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010537225A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011507807A (ja
JP2011507807A5 (https=
Inventor
ジュヨン，ガーン
ジャーン，ジーホーン
コルビン，イアン
チェン，ジュエン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University Health Network
Original Assignee
University Health Network
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Health Network filed Critical University Health Network
Publication of JP2011507807A publication Critical patent/JP2011507807A/ja
Publication of JP2011507807A5 publication Critical patent/JP2011507807A5/ja
Application granted granted Critical
Publication of JP5658568B2 publication Critical patent/JP5658568B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6917—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a lipoprotein vesicle, e.g. HDL or LDL proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6919—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a ribbon or a tubule cochleate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0076—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion
    • A61K49/0082—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion micelle, e.g. phospholipidic micelle and polymeric micelle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
    • G01N33/54346—Nanoparticles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/585—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex
    • G01N33/587—Nanoparticles
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Medical Informatics (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
JP2010537225A 2007-12-12 2008-12-12 高密度リポタンパク質様ペプチド−リン脂質足場（「ｈｐｐｓ」）ナノ粒子 Expired - Fee Related JP5658568B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US1323307P 2007-12-12 2007-12-12
US61/013,233 2007-12-12
US10450608P 2008-10-10 2008-10-10
US61/104,506 2008-10-10
PCT/CA2008/002203 WO2009073984A1 (en) 2007-12-12 2008-12-12 High-density lipoprotein-like peptide-phospholipid scaffold ('hpps') nanoparticles

Publications (3)

Publication Number Publication Date
JP2011507807A JP2011507807A (ja) 2011-03-10
JP2011507807A5 JP2011507807A5 (https=) 2012-02-02
JP5658568B2 true JP5658568B2 (ja) 2015-01-28

Family

ID=40755223

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010537225A Expired - Fee Related JP5658568B2 (ja) 2007-12-12 2008-12-12 高密度リポタンパク質様ペプチド−リン脂質足場（「ｈｐｐｓ」）ナノ粒子

Country Status (6)

Country Link
US (1) US20110020242A1 (https=)
EP (1) EP2229411B1 (https=)
JP (1) JP5658568B2 (https=)
CN (2) CN105903029A (https=)
CA (1) CA2708719A1 (https=)
WO (1) WO2009073984A1 (https=)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8734853B2 (en) 2008-11-17 2014-05-27 University Of North Texas Health Science Center At Fort Worth HDL particles for delivery of nucleic acids
US20100233270A1 (en) 2009-01-08 2010-09-16 Northwestern University Delivery of Oligonucleotide-Functionalized Nanoparticles
WO2011035279A2 (en) * 2009-09-21 2011-03-24 Board Of Regents, The University Of Texas System Nanocarriers for imaging and therapy applications
US10498796B2 (en) * 2009-10-16 2019-12-03 Real Innovations International Llc System and method for providing real-time data
AU2011207563B2 (en) 2010-01-19 2016-03-10 Northwestern University Synthetic nanostructures including nucleic acids and/or other entities
KR101405403B1 (ko) * 2010-01-20 2014-06-11 주식회사 진코스 클로린 유도체와 불포화 지방산의 접합체, 이를 함유하는 광감작제, 및 이를 포함하는 광역학 치료에 사용하기 위한 암 치료용 조성물
US9592268B2 (en) 2011-05-23 2017-03-14 Cornell University Endothelium protective materials and methods of use
CA2883080A1 (en) * 2011-08-26 2013-03-07 Vecoy Nanomedicines Ltd. Pathogen and substance traps
WO2013033513A1 (en) * 2011-08-31 2013-03-07 University Of Georgia Research Foundation, Inc. Apoptosis-targeting nanoparticles
AU2013222238A1 (en) * 2012-02-22 2014-09-18 Northwestern University Nanostructures for treating cancers and other conditions
JP2014129317A (ja) * 2012-02-23 2014-07-10 Canon Inc 光音響造影剤用色素含有ナノ粒子
CN102766215B (zh) 2012-06-07 2014-08-13 华中科技大学 一种具有协同靶向诊疗鼻咽癌功能的多肽和携带此多肽的纳米颗粒及其应用
CN104736181A (zh) 2012-08-10 2015-06-24 北德克萨斯大学健康科学中心 包含靶向聚氨基酸与脂肪酸之缀合物的药物递送载剂
EP3024936B1 (en) 2013-07-25 2019-09-04 Exicure, Inc. Spherical nucleic acid-based constructs as immunostimulatory agents for prophylactic and therapeutic use
US10568898B2 (en) 2013-08-13 2020-02-25 Northwestern University Lipophilic nanoparticles for drug delivery
JP6692748B2 (ja) 2013-09-26 2020-05-13 ナショナル ユニヴァーシティー オブ シンガポール リゾホスファチジルコリンの足場を利用する組成物及び方法
US10182988B2 (en) 2013-12-03 2019-01-22 Northwestern University Liposomal particles, methods of making same and uses thereof
US10398663B2 (en) 2014-03-14 2019-09-03 University Of Georgia Research Foundation, Inc. Mitochondrial delivery of 3-bromopyruvate
CN103910802B (zh) * 2014-04-24 2017-01-11 华中科技大学 一种促进树突细胞摄取抗原肽的多肽、促进树突细胞摄取抗原肽的纳米颗粒及其应用
US10413565B2 (en) 2014-04-30 2019-09-17 Northwestern University Nanostructures for modulating intercellular communication and uses thereof
TR201908550T4 (tr) 2014-06-04 2019-07-22 Exicure Inc Profilaktik veya terapötik uygulamalar için lipozomal sferik nükleik asitler tarafından immün modülatörlerin çok değerlikli teslimi.
US20170128591A1 (en) * 2014-06-20 2017-05-11 University Health Network Peptide Containing Porphyrin Lipid Nanovesicles
WO2016028940A1 (en) 2014-08-19 2016-02-25 Northwestern University Protein/oligonucleotide core-shell nanoparticle therapeutics
CR20170181A (es) 2014-10-06 2017-05-31 Exicure Inc Compuestos anti-tnf
US11213593B2 (en) 2014-11-21 2022-01-04 Northwestern University Sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
US10517924B2 (en) 2014-11-24 2019-12-31 Northwestern University High density lipoprotein nanoparticles for inflammation
US10078092B2 (en) 2015-03-18 2018-09-18 Northwestern University Assays for measuring binding kinetics and binding capacity of acceptors for lipophilic or amphiphilic molecules
JP2018528257A (ja) 2015-07-10 2018-09-27 ペプティノボ・バイオファーマ・リミテッド・ライアビリティ・カンパニーＰｅｐｔｉｎｏｖｏ Ｂｉｏｐｈａｒｍａ， ＬＬＣ 疎水性薬剤の効能を改善するための配合物
CN106831997B (zh) * 2015-12-03 2020-04-24 中国科学院苏州纳米技术与纳米仿生研究所 多肽、脂蛋白样纳米粒子及其应用
EP3411012A4 (en) 2016-02-04 2019-08-28 Alastin Skincare, Inc. COMPOSITIONS AND METHODS FOR INVASIVE AND NON-INVASIVE PROCEDURAL SKIN CARE
US10967072B2 (en) 2016-04-27 2021-04-06 Northwestern University Short interfering RNA templated lipoprotein particles (siRNA-TLP)
CN109640959B (zh) 2016-04-29 2023-03-17 西奈山伊坎医学院 靶向先天免疫系统以诱导长期耐受性及解决动脉粥样硬化中的巨噬细胞累积
EP3452598A4 (en) 2016-05-06 2020-04-29 Exicure, Inc. LIPOSOMAL SPHERICAL NUCLEIC ACID (ANS) CONSTRUCTS HAVING ANTISENSE OLIGONUCLEOTIDES (ASO) FOR THE SPECIFIC INACTIVATION OF INTERLEUKIN 17 RECEPTOR RNA
WO2018170390A1 (en) * 2017-03-17 2018-09-20 Senti Biosciences, Inc. Immunomodulating cell circuits
WO2018191619A1 (en) 2017-04-13 2018-10-18 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
US11696954B2 (en) 2017-04-28 2023-07-11 Exicure Operating Company Synthesis of spherical nucleic acids using lipophilic moieties
MX2020000387A (es) 2017-07-13 2020-08-17 Univ Northwestern Método general y directo para preparar nanopartículas de estructura organometálica funcionalizadas con oligonucleotidos.
KR102757675B1 (ko) 2017-08-03 2025-01-20 앨러스틴 스킨케어, 인크. 피부 이완 및 신체 윤곽의 개선을 위한 조성물 및 방법
CN107573418B (zh) * 2017-08-21 2020-09-25 华中科技大学 肿瘤相关巨噬细胞双靶向多肽、纳米颗粒、制备及应用
EP3713548A4 (en) * 2017-11-21 2021-06-23 Icahn School of Medicine at Mount Sinai Promoting trained immunity with therapeutic nanobiologic compositions
CN108143719B (zh) * 2017-12-27 2022-01-25 华中科技大学 一种携载多肽的纳米脂质体及其制备方法和应用
WO2019133914A1 (en) * 2017-12-29 2019-07-04 Wayne State University Method of treatment for solid tumors containing hypoxia and/or stroma features
CN108685875B (zh) * 2018-07-30 2020-11-03 中国药科大学 一种抗阿尔兹海默症的天然纳米粒-药物组合物及其制备方法和应用
WO2020028694A1 (en) 2018-08-02 2020-02-06 ALASTIN Skincare, Inc. Liposomal compositions and methods of use
CN110123761B (zh) * 2019-05-07 2022-09-06 沈阳药科大学 一种仿生型高密度脂蛋白纳米粒及其制备和应用
US12319711B2 (en) 2019-09-20 2025-06-03 Northwestern University Spherical nucleic acids with tailored and active protein coronae
US12378560B2 (en) 2019-10-29 2025-08-05 Northwestern University Sequence multiplicity within spherical nucleic acids
CN111012555A (zh) * 2019-12-03 2020-04-17 刘训伟 载放射性核素微纳米涂层支架及其制备方法
CN111150834A (zh) * 2020-01-06 2020-05-15 吉林大学 一种载脂蛋白e与盐霉素复合纳米粒及制备方法和应用
CN111494641B (zh) * 2020-04-22 2021-08-03 南开大学 肿瘤微环境响应性的表面电荷可反转纳米药物递送载体
CA3199462A1 (en) * 2020-10-23 2022-04-28 Northwestern University Hydrophobic drugs in organic core high density lipoprotein (hdl) nanoparticles
AU2022239614A1 (en) 2021-03-19 2023-10-12 Icahn School Of Medicine At Mount Sinai Compounds for regulating trained immunity, and their methods of use
WO2022231724A1 (en) * 2021-04-28 2022-11-03 The Regents Of The University Of California Adipocyte-derived anti-cancer lipid droplets
US20240307308A1 (en) * 2021-07-13 2024-09-19 University Health Network Porphyrin nanovesicle with fatty acid conjugate
WO2023230711A1 (en) * 2022-05-31 2023-12-07 University Health Network Lipid nanoparticle for the delivery of rna
CN116650659A (zh) * 2023-06-08 2023-08-29 弘亮(上海)生物医药科技有限公司 ApoA1短肽和微管蛋白抑制剂的偶联物及其自组装纳米制剂
CN116602923A (zh) * 2023-07-20 2023-08-18 暨南大学附属第一医院（广州华侨医院） 一种用于关节炎治疗的靶向仿生纳米治疗载体系统
US20250345454A1 (en) * 2024-05-09 2025-11-13 Peptinovo Biopharma Inc. Chemotherapeutic paclitaxel based micellular nanoparticles

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166214A (en) * 1988-12-05 1992-11-24 Du Pont Merck Pharmaceutical Company Use of imidazoles for the treatment of atherosclerosis
WO1993010755A1 (en) 1991-11-25 1993-06-10 Richardson-Vicks, Inc. Compositions for regulating skin wrinkles and/or skin atrophy
CZ294130B6 (cs) 1996-04-23 2004-10-13 Theáprocterá@Ágambleácompany Kosmetický způsob regulace velikosti pórů v kožní tkáni savců
US6664230B1 (en) * 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US20040234588A1 (en) * 2000-09-21 2004-11-25 University Of Georgia Research Foundation, Inc. Artificial lipoprotein carrier system for bioactive materials
JP4995423B2 (ja) * 2002-12-03 2012-08-08 ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート 物質を血液−脳関門を渡って輸送するための人工低密度リポタンパク質キャリア
US8097283B2 (en) * 2004-01-15 2012-01-17 Mount Sinai School Of Medicine Methods and compositions for imaging
US20080253960A1 (en) 2004-04-01 2008-10-16 The Trustees Of The University Of Pennsylvania Center For Technology Transfer Lipoprotein-Based Nanoplatforms
KR101185609B1 (ko) * 2004-07-16 2012-09-24 트러스티즈 오브 터프츠 칼리지 아포리포단백질 ａ１ 미메틱 및 이의 용도
CN101346393B (zh) * 2005-11-02 2015-07-22 普洛体维生物治疗公司 修饰的siRNA分子及其应用
WO2007145659A1 (en) * 2005-11-10 2007-12-21 The Regents Of The University Of California Synthetic ldl as targeted drug delivery vehicle

Also Published As

Publication number Publication date
EP2229411A4 (en) 2015-03-04
CN102027019A (zh) 2011-04-20
CN105903029A (zh) 2016-08-31
EP2229411B1 (en) 2019-02-27
JP2011507807A (ja) 2011-03-10
EP2229411A1 (en) 2010-09-22
WO2009073984A1 (en) 2009-06-18
US20110020242A1 (en) 2011-01-27
CA2708719A1 (en) 2009-06-18

Similar Documents

Publication Publication Date Title
JP5658568B2 (ja) 高密度リポタンパク質様ペプチド−リン脂質足場（「ｈｐｐｓ」）ナノ粒子
US20080253960A1 (en) Lipoprotein-Based Nanoplatforms
US8361494B2 (en) Biomimetic iron-oxide-containing lipoprotein and related materials
Singh et al. RGD-TPGS decorated theranostic liposomes for brain targeted delivery
Grange et al. Combined Delivery and Magnetic Resonance Imaging of Neural Cell Adhesion Molecule–Targeted Doxorubicin-Containing Liposomes in Experimentally Induced Kaposi's Sarcoma
Song et al. Development of a multi-target peptide for potentiating chemotherapy by modulating tumor microenvironment
Lainé et al. Conventional versus stealth lipid nanoparticles: formulation and in vivo fate prediction through FRET monitoring
Wang et al. pH-activated, mitochondria-targeted, and redox-responsive delivery of paclitaxel nanomicelles to overcome drug resistance and suppress metastasis in lung cancer
Zhang et al. Dual-responsive doxorubicin-loaded nanomicelles for enhanced cancer therapy
Shao et al. A smart multifunctional nanoparticle for enhanced near-infrared image-guided photothermal therapy against gastric cancer
CN102573914B (zh) 卟啉纳米囊泡
Wang et al. MMP-2-controlled transforming micelles for heterogeneic targeting and programmable cancer therapy
Corbin et al. Near-infrared fluorescent imaging of metastatic ovarian cancer using folate receptor-targeted high-density lipoprotein nanocarriers
Aryasomayajula et al. Multifunctional liposomes
Liu et al. Transferrin-conjugated liposomes loaded with carnosic acid inhibit liver cancer growth by inducing mitochondria-mediated apoptosis
JP2016531086A (ja) 蛍光固形脂質ナノ粒子組成物およびその製法
Zhang et al. Lanthanide–cyclen–camptothecin nanocomposites for cancer theranostics guided by near-infrared and magnetic resonance imaging
Cen et al. Doxorubicin-loaded liposome with the function of “killing two birds with one stone” against glioma
US20060216342A1 (en) Micelle delivery system loaded with a pharmaceutical agent
Wang et al. Self-assembly of photosensitive and radiotherapeutic peptide for combined photodynamic-radio cancer therapy with intracellular delivery of miRNA-139-5p
Ahmed et al. Dual-functional peptide driven liposome codelivery system for efficient treatment of doxorubicin-resistant breast cancer
Han et al. Lipoprotein-inspired nanocarrier composed of folic acid-modified protein and lipids: preparation and evaluation of tumor-targeting effect
Jiao et al. Intelligent porphyrin nano-delivery system for photostimulated and targeted inhibition of angiogenesis
Dai et al. Low-density lipoprotein: a versatile nanoscale platform for targeted delivery
Qian et al. Development and evaluation of curcumin nano-niosomes for glioma-targeted therapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111212

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20111212

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130808

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131107

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131114

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131206

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131213

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140114

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140116

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140501

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20141031

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20141128

R150 Certificate of patent or registration of utility model

Ref document number: 5658568

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees